Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,226,571
  • Shares Outstanding, K 43,620
  • Annual Sales, $ 11,280 K
  • Annual Income, $ -83,300 K
  • 60-Month Beta 0.79
  • Price/Sales 266.27
  • Price/Cash Flow N/A
  • Price/Book 8.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.77
  • Number of Estimates 6
  • High Estimate -0.67
  • Low Estimate -0.93
  • Prior Year -0.59
  • Growth Rate Est. (year over year) -30.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.41 +46.74%
on 11/21/19
74.02 -0.07%
on 12/13/19
+20.16 (+37.47%)
since 11/13/19
3-Month
36.20 +104.34%
on 10/02/19
74.02 -0.07%
on 12/13/19
+26.49 (+55.79%)
since 09/13/19
52-Week
24.07 +207.31%
on 12/26/18
82.49 -10.33%
on 06/20/19
+45.68 (+161.47%)
since 12/13/18

Most Recent Stories

More News
uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B

~ Sustained FIX Activity at Therapeutic Levels Up to 50% of Normal at One Year After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~

QURE : 73.97 (+7.39%)
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics

The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics

QURE : 73.97 (+7.39%)
BMRN : 80.17 (-0.90%)
SGMO : 8.51 (-1.96%)
SRPT : 132.05 (+31.43%)
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal

Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.

RHHBY : 38.1600 (-0.73%)
BMY : 63.82 (-0.19%)
QURE : 73.97 (+7.39%)
SRPT : 132.05 (+31.43%)
SGMO : 8.51 (-1.96%)
BMRN : 80.17 (-0.90%)
BOLD : 59.40 (+0.05%)
Gene Therapy the Next Best Thing: Here's Why (Revised)

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

NTLA : 16.50 (-1.84%)
VRTX : 218.98 (-0.71%)
QURE : 73.97 (+7.39%)
MGTX : 21.02 (+2.44%)
PIRS : 3.29 (-4.91%)
Gene Therapy the Next Best Thing: Here's Why

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

NTLA : 16.50 (-1.84%)
VRTX : 218.98 (-0.71%)
QURE : 73.97 (+7.39%)
MGTX : 21.02 (+2.44%)
PIRS : 3.29 (-4.91%)
Biotechs Move Forward Developing Latest Targeted Therapies for Acute Myeloid Leukemia

So it is not surprising that there is a lot of money and research resources being devoted to find new therapies for Acute Myeloid Leukemia (AML), many of which are in the targeted drugs arena. AML is the...

MBRX : 1.02 (+0.99%)
BOLD : 59.40 (+0.05%)
OTLK : 1.24 (+9.73%)
AXSM : 46.79 (-3.66%)
QURE : 73.97 (+7.39%)
uniQure to Participate in Multiple Upcoming Industry Conferences in December

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 02, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...

QURE : 73.97 (+7.39%)
uniQure N.V. (QURE) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in uniQure N.V. (QURE).

QURE : 73.97 (+7.39%)
uniQure Announces Clinical Data Presentations at the 61st American Society of Hematology (ASH) Annual Meeting

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that six data presentations will be delivered...

QURE : 73.97 (+7.39%)
uniQure Announces the Allowance of New Patent Providing Further Protection of the Padua and Padua-Related Variants of Factor IX in Gene Therapy

~ Third uniQure U.S. Patent Covering the Treatment of Hemophilia B and Other Bleeding Disorders using FIX-Padua in AAV Gene Therapy ~

QURE : 73.97 (+7.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade QURE with:

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

2nd Resistance Point 78.28
1st Resistance Point 76.13
Last Price 73.97
1st Support Level 69.71
2nd Support Level 65.44

See More

52-Week High 82.49
Last Price 73.97
Fibonacci 61.8% 60.17
Fibonacci 50% 53.28
Fibonacci 38.2% 46.39
52-Week Low 24.07

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar